$CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy$

CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy

Saved in:

Bibliographic Details
Main Authors:	Hui Luo, Tongjuan Li, Fankai Meng, Zhenya Hong, Yang Cao, Gaoxiang Wang, Liang Huang, Xiaoxi Zhou
Format:	Article
Language:	English
Published:	China Anti-Cancer Association 2025-05-01
Series:	Cancer Biology & Medicine
Online Access:	https://www.cancerbiomed.org/content/22/5/496
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and safety of a novel CD19, CD22 dual-targeted fully human loop bi-CAR-T for the treatment of relapsed/refractory B cell non-Hodgkin lymphoma
by: Hanyu Wang, et al.
Published: (2025-06-01)

Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma
by: Sophia Stock, et al.
Published: (2025-01-01)

Be cautious to adopt a second CAR T-cell infusion after failure of CD19/CD22 cocktail CAR T-cell therapy in relapsed/refractory B-NHL
by: Gaoxiang Wang, et al.
Published: (2025-03-01)

Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma
by: Evgenii Shumilov, et al.
Published: (2025-08-01)

Efficacy and safety of zanubrutinib combined with chimeric antigen receptor T-cell therapy targeting CD19 in refractory or relapsed diffuse large B cell lymphoma: A retrospective analysis
by: Jinhuan Xu, et al.
Published: (2025-01-01)

Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
by: Narendranath Epperla, et al.
Published: (2024-11-01)

Use of locally produced anti-CD19 CAR-T cells in the treatment of relapsed/refractory B-cell lymphomas in adults
by: N. E. Konoplya, et al.
Published: (2023-09-01)

CAR T- cell therapy provides an opportunity for further consolidation treatment for relapsed or refractory adult Burkitt lymphoma patients
by: Rui Liu, et al.
Published: (2025-05-01)

Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma
by: Wei Liu, et al.
Published: (2024-04-01)

Early Epcoritamab Administration Revives CAR‐T Cells in Relapsed/Refractory B‐Cell Lymphomas
by: Kensuke Yanashima, et al.
Published: (2025-06-01)

Incidentally cured psoriasis in a patient with refractory/relapsed diffuse large B-cell lymphoma receiving CD19 CAR-T cell therapy: a case report
by: Song-yun Wang, et al.
Published: (2024-10-01)

CAR-T cell therapy in older adults with relapsed/refractory LBCL: benefits and challenges
by: Matthew J Frigault, et al.
Published: (2025-06-01)

Anti-CD19 CAR-T cell therapy in relapsed/refractory t(8;21) acute myeloid leukemia with aberrant CD19 expression
by: Xiaomin Zhang, et al.
Published: (2025-07-01)

The Role of Radiotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Post-CAR-T Therapy: A Systematic Literature Review
by: Andrea Emanuele Guerini MD, et al.
Published: (2025-06-01)

Allogeneic CAR-engineered cellular therapy for relapsed and refractory large B cell lymphoma: a systematic review and meta-analysis
by: Alexander Biederstädt, et al.
Published: (2025-07-01)

Response‐adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T‐cell therapy in relapsed/refractory large B‐cell lymphoma: A retrospective observational study
by: Rong Shen, et al.
Published: (2025-04-01)

Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma
by: Patrick Born, et al.
Published: (2025-06-01)

CD20×CD3 bispecific antibody achieved significant efficacy in patients with large B-cell lymphoma relapsing after or refractory to CAR-T therapy: a systematic review and meta-analysis
by: Jing Shen, et al.
Published: (2025-08-01)

Real-World Characterization of Toxicities and Medication Management in Recipients of CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma in Nova Scotia, Canada
by: Jenna Shaw, et al.
Published: (2024-12-01)

Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia
by: Tingting Yang, et al.
Published: (2025-01-01)

CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS
by: Ugo Testa, et al.
Published: (2024-01-01)

Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma
by: Yok-Lam Kwong, et al.
Published: (2025-03-01)

Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma
by: Rossana Di Staso, et al.
Published: (2024-11-01)

Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma
by: Narendranath Epperla, et al.
Published: (2025-01-01)

Clinical outcomes of chimeric antigen receptor T-cell therapy following autologous hematopoietic stem cell transplantation in 38 patients with refractory/relapsed primary or secondary central nervous system lymphoma
by: Jiaying Wu, et al.
Published: (2024-11-01)

Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia
by: Qianyi Zhou, et al.
Published: (2025-03-01)

CAR-T CELL THERAPY IN LARGE B CELL LYMPHOMA
by: Ugo Testa, et al.
Published: (2023-10-01)

Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy
by: Jessica S. Little, et al.
Published: (2025-08-01)

Therapies and outcomes following extramedullary relapse of pediatric and young adult ALL after CD19 CAR T-cell therapy
by: Barbara D. Friedes, et al.
Published: (2025-01-01)

Case report: CAR-T therapy demonstrated safety and efficacy in relapsed/refractory diffuse large B-cell lymphoma patients complicated with hepatitis B-related cirrhosis
by: Danqing Kong, et al.
Published: (2024-12-01)

Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia
by: Ya Hwee Tan, et al.
Published: (2025-02-01)

Balance and management of CRS and infection following CD19-targeted CAR T-cell therapy in primary refractory high-grade B-cell lymphoma: a case report
by: Nannan Lu, et al.
Published: (2025-07-01)

Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies
by: Allison M. Bock, et al.
Published: (2025-07-01)

Metabolic profile evolution in relapsed/refractory B-cell non-Hodgkin lymphoma patients treated with CD19 chimeric antigen receptor T-cell therapy and implications in clinical outcome
by: Serena De Matteis, et al.
Published: (2024-12-01)

Real-world Australian experience with tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma—importance of pre-CAR-T optimization
by: Phoebe Joy Ho, et al.
Published: (2025-08-01)

EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma
by: Xiang Zhou, et al.
Published: (2024-10-01)

The impact of antibiotic use on outcomes of relapsed/refractory multiple myeloma patients treated with CAR-T therapy
by: Lingling Yin, et al.
Published: (2025-04-01)

Maximizing the Benefit of CAR T-Cell Therapy in Lymphoma and Multiple Myeloma
by: Federico Simonetta
Published: (2022-10-01)

CAR-T CELL THERAPY IN LYMPHOMAS: EXPANSİON OF INDICATIONS AND NEW APPROACHES
by: Ayfer Gedük
Published: (2024-12-01)

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)